Synthesis of 10-methyl-8,10-diazabicyclo[4.3.1]decane as a new building block for nicotinic modulators

Osvaldas Paliulis,^a Dan Peters,^b Wolfgang Holzer^c and Algirdas Šačkus^{a*}

^a*Kaunas University of Technology, Institute of Synthetic Chemistry, Radvilėnų pl. 19, Kaunas, LT-50254, Lithuania*

^b*DanPET AB, Rosenstigen 7, Malmö, 216 19, Sweden*

^c*Department of Drug and Natural Product Synthesis, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, Vienna, A-1090, Austria*

E-mail: algirdas.sackus@ktu.lt

Abstract

A convenient method for the synthesis of 10-methyl-8,10-diazabicyclo[4.3.1]decane, possessing a novel diazabicyclic ring system, as an important synthetic organic chemistry building block was developed using octanedioic acid as a starting material. The key transformation in the 5-step synthesis sequence involved a reaction of dimethyl 2,7-dibromooctanoate with methylamine, which resulted in the formation of *cis*-dimethyl 1-methylazepan-2,7-dicarboxylate. The latter was further transformed into bicyclic 8-benzyl-10-methyl-8,10-diazabicyclo[4.3.1]decane-7,9-dione under heating with benzylamine. Reduction of the formed bicyclic dione with lithium aluminium hydride resulted in 8-benzyl-10-methyl-8,10-diazabicyclo[4.3.1]decane, and hydrogenolysis efficiently yielded the target product.

Keywords: Octanedioic acid, *meso*-dimethyl 2,7-dibromooctanedioate, azepane, 8,10-diazabicyclo[4.3.1]decane

Introduction

Diazabicycloalkanes are important synthetic precursors in the preparation of compounds with a variety of biomedical applications. For example, derivatives of 3,8-diazabicyclo[3.2.1]octane and 1,4-diazabicyclo[3.2.2]nonane were used as the starting materials for the synthesis of various biologically active molecules, including α -7 nicotinic acetylcholine receptor agonists, which can be used for the treatment of diseases or disorders related to the central nervous system (CNS) and peripheral nervous system (PNS).¹⁻⁶ Adducts of 3,8-diazabicyclo[3.2.1]octane, 1,4-diazabicyclo[3.2.2]nonane and other similar diazabicycles with quinolones resulted in products with significant antibacterial activity.⁷ 1,4-Diazabicyclo[3.2.2]nonanes also serve as precursors

in the preparation of ^{18}F isotope-containing potential radiotracers for imaging α -7 nicotinic acetylcholine receptors,^{8,9} whereas 3,10-diazabicyclo[4.3.1]decane derivatives are used in the synthesis of ^{11}C -labeled serotonin transporter ligands.¹⁰ Recently, it was shown that 10-methyl-8,10-diazabicyclo[4.3.1]decane derivatives are potent nicotinic modulators and may be useful in the treatment of diseases related to the cholinergic system of the CNS or PNS.¹¹ However, the synthetic route of 10-methyl-8,10-diazabicyclo[4.3.1]decane and the spectral and physical characteristics of this compound have not been previously determined. To fill this gap, the synthesis of 10-methyl-8,10-diazabicyclo[4.3.1]decane is presented in the current work.

Various synthetic methods have been described in the literature for diazabicycles, which vary depending on the size of the ring system, the position of the ring nitrogen atoms and the availability of starting materials. For example, 1,4-diazabicyclo[3.2.2]nonane was prepared from 3-quinuclidinone oxime employing the strong acid-catalysed Beckmann rearrangement. Heating of the obtained by a such way 1,4-diazabicyclo[3.2.2]nonan-3-one with lithium aluminium hydride produced the target bicyclic compound.¹² The construction of 2,7-diazabicyclo[3.1.1]nonanes was carried out starting from 2-(2-cyano-2-phenylethyl)aziridines *via* their transformation to 2-chloromethyl-4-phenylpiperidine-4-carbonitriles.¹³ The synthesis of 3,8-diazabicyclo[3.2.1]octane was performed by a multi-step procedure starting from dimethyl *meso*-2,5-dibromoadipate *via* its conversion to *cis*-dimethyl 1-benzylpyrrolidine-2,5-dicarboxylate. Reaction of this intermediate compound with a second equivalent of benzylamine resulted in 3,8-dibenzyl-3,8-diazabicyclo[3.2.1]octan-2,4-dione, which was reduced and resulted in the final bicyclic product after hydrogenolysis.^{14,15} Similar synthesis strategies were employed for the preparation of 8-methyl- and 8-ethyl-3,8-diazabicyclo[3.2.1]octanes.¹⁶ Recently, a new method for the preparation of 3-benzyl-3,8-diazabicyclo[3.2.1]octane was proposed based on the reaction of benzylamine with mesylated 2,5-dihydroxymethylpyrrolidine, which is a product obtained from *meso*-2,5-dibromoadipate using a multi-step procedure.¹⁷

Results and Discussion

To synthesize the desired 10-methyl-8,10-diazabicyclo[4.3.1]decane, we have selected a strategy in which the main step included the synthesis of intermediate *cis*-azepane dicarboxylate starting from commercially available suberic (octanedioic) acid, which was followed by the transformation of this intermediate into bicyclic 8,10-diazabicyclo[4.3.1]decane (Scheme 1). A similar strategy has been successfully applied for the preparation of 8-alkyl-3,8-diazabicyclo[3.2.1]octanes from adipic acid,¹⁵ as mentioned above. We initiated synthesis by preparing dimethyl 2,7-dibromooctanedioate (**2**) from suberic acid (**1**). It is known that bromination of suberic acid under Hell-Volhard reaction conditions results in racemic and *meso*-2,7-dibromosuberic acids as a mixture of diastereomers.¹⁸ In 1981, Tokuda et al. described a protocol to afford dimethyl 2,7-dibromooctanedioate as a mixture of *rac* and *meso* isomers *via* bromination of octanedioyl dichloride with a mixture of phosphorus tribromide and dry bromine

followed by treatment of the crude intermediate product with absolute methanol.¹⁹ However, it was shown by Blackman and Baltzly¹⁶ that the formation of the corresponding cyclic amines, which are in the required *cis*-configuration and can only serve as precursors of bicyclic derivatives, took part, when the starting dibrominated alkanedioate contains the *meso*-configuration, whereas the dibrominated *rac*-alkanedioate preferentially results in the *trans*-configuration product.

We started the preparation of dimethyl 2,7-dibromooctanedioate (**2**) by transformation of suberic acid (**1**) to octanedioyl dichloride (Scheme 1) *via* reaction with thionyl chloride as it was described in the aforementioned work.¹⁹ However, bromination of the obtained intermediate octanedioyl dichloride was carried out by us applying radical reaction pathway, when after addition of bromine the reaction flask was continuously irradiated with a 200 W mercury lamp. Treatment of the reaction mixture with methanol and distillation of the obtained product under high vacuum, resulted in the target dimethyl 2,7-dibromooctanedioate (**2**) in 84% isolated yield. The ¹H- and ¹³C-NMR spectra of **2** revealed one set of signals, which indicated the formation of one of the two possible diastereomers only, that is, the radical bromination proceeded diastereoselectively.

The second and crucial step of the synthesis was the formation of the azepane cycle by the reaction of dibromodiester (**2**) with methylamine. It is known that diethyl *meso*-2,5-dibromoadipate underwent cyclisation to the corresponding 5-membered pyrrolidine derivative by reacting with methylamine at room temperature.¹⁵ When the reaction of dibromodiester (**2**) with methylamine was performed under similar reaction conditions, the desired cyclic product, dimethyl *cis*-1-methylazepan-2,7-dicarboxylate (**4**), was separated by column chromatography with a 6% yield only. However, when the reaction temperature was elevated to 120 °C, a complex mixture of products was produced, from which the desired azepane **4** was obtained by yield of 28%. Notably, analysis of the crude product (before vacuum distillation) using ¹H and ¹³C NMR spectroscopy and liquid chromatography/mass-spectrometry revealed the presence in the mixture of the second diastereomer, dimethyl *trans*-1-methylazepan-2,7-dicarboxylate (the ratio of *cis*/*trans* products in a crude mixture was approximately 10/1 in the ¹H NMR spectrum). The stereochemical outcome of the reaction can be rationalised by the S_N2-type nucleophilic displacement of one of the bromine atoms of *meso*-dimethyl 2,7-dibromooctanedioate **2** by the nitrogen atom of methyl amine, which resulted in a Walden inversion to form the intermediate **3**. Compound **3** undergoes ring-closure by the substitution of the second bromine atom to provide the final product **4**, which is in the *cis*-configuration. The presence in the crude reaction product of the corresponding *trans*-isomer as a side-product can be explained by a partial transformation of the starting *meso*-**2** to *rac*-**2** under the reaction conditions.¹⁶ It is important to note, that the use of milder reaction conditions or the application of aromatic solvents such as toluene or xylene instead THF, did not increase the yield of the target product **4**.

Using liquid chromatography/mass-spectrometry it was established also that during the reaction of **2** with methylamine at elevated temperature, the ester groups of intermediate substrates underwent partially the reactions of aminolysis to yield the corresponding amides as

side products, including methylamide **5a**, with lowering the yield of the target product. Moreover, the amide **5a** can take part in the intramolecular cyclisation to form bicyclic 8,10-dimethyl-8,10-diazabicyclo[4.3.1]decan-7,9-dione **6a**. Indeed, heating of the reaction residue obtained after separation of **4** at 205 °C, afforded imide **6a** with the isolated yield 10%.

Scheme 1. Synthesis of 8,10-diazabicyclo[4.3.1]decan-7,9-diones.

Figure 1. (a) ^{13}C chemical shifts of **5b** (ppm; ref. TMS in $\text{DMSO}-d_6$). (b) Relevant NOE correlations.

It is worth to point out that azepane ring is present in various natural medicinally important bioactive compounds, such as bengamides²⁰⁻²² and balanols^{23,24} and their synthetic analogues, while azepane quaternary amino acids found application in the preparation of conformationally constrained peptidomimetics.^{25,26}

Furthermore, we investigated the aminolysis of diester **4** with benzylamine. To determine the optimum reaction conditions for increasing the yield, this reaction was studied under various conditions. Heating of diester **4** with benzylamine in xylene at 120 °C for 20 h, afforded monoamide **5b** as a main product in a 69% yield. The structure of **5b** was confirmed by methods of NMR spectroscopy. The assignments presented in **Fig. 1a, b** were based on the combined application of standard NMR techniques such as NOESY, APT, HSQC and HMBC.²⁷

When the aminolysis of diester **4** with benzylamine was performed at 160 °C (oil bath temperature) for 48 h, it resulted in a mixture of monoamide **5b**, and the corresponding diamide, whereas only traces of bicyclic imide **6b** were detected. Much better yield of **6b** was obtained, when after heating at 160 °C for a prolonged time, the reaction mixture was placed under high vacuum to remove unreacted reagents, and the residue was heated at elevated temperatures (205 °C) for 24 h. Vacuum distillation of the obtained mixture and subsequent crystallisation of the crude product resulted in bicyclic imide **6b** in a 42% yield

Scheme 2. Synthesis of 8,10-diazabicyclo[4.3.1]decanes.

Finally, the reduction of **6a, b** with LiAlH₄ in dioxane resulted in 8,10-dimethyl- and 8-benzyl-10-methyl-8,10-diazabicyclo[4.3.1]decanes **7a** and **7b**, respectively (Scheme 2). Hydrogenolysis in ethanol of **7b** gave the target product **8**. The ¹³C NMR spectrum of compound **8** contained four signals due to ring carbons at 55.4 (C-1, C-6), 49.6 (C-7, C-9), 32.6 (C-2, C-5) and 26.1 (C-3, C-4) and a signal of the methyl group at 42.5 ppm. The freshly distilled 10-methyl-8,10-diazabicyclo[4.3.1]decane (**8**) is a waxy solid that absorbs moisture and carbon dioxide upon exposure to air.

Conclusions

In summary, we have developed an efficient five-step method for the synthesis of 10-methyl-8,10-diazabicyclo[4.3.1]decane, which is an important scaffold for the preparation of such biologically active compounds, as nicotinic modulators, on a multigram scale starting from commercially available suberic acid.

Experimental Section

General. All starting materials were purchased from Aldrich or Fluka. Melting points were determined in open capillary tubes on a Büchi B-560 melting point apparatus and are uncorrected. Infrared spectra were recorded with a Bruker Tensor 27 spectrometer using KBr pellets, NaCl windows or a single reflection diamond ATR accessory. ATR spectra are not corrected. Raman scattering spectra were recorded with a Bruker FT-RAMII spectrometer. ^1H NMR spectra were recorded at 300 MHz on a Varian Inova or at 400 MHz on a Bruker Avance III spectrometer; ^{13}C NMR spectra were registered at 75 MHz or 100 MHz, respectively. Chemical shifts, expressed in ppm, were relative to tetramethylsilane (TMS). High-resolution ESI-TOF mass spectra were measured on a Bruker maXis 4G spectrometer. LC/MS measurements were carried out on a Shimadzu LCMS-2020 system. Vacuum distillation was performed on a Büchi Model B580 GKR oven. Elemental analyses were conducted using a Elemental Analyzer CE-440 (Exeter Analytical, Inc.) by the Microanalytical Laboratory, Department of Organic Chemistry, Kaunas University of Technology.

***meso*-Dimethyl 2,7-dibromooctanedioate (2).** To a round-bottom flask (1000 mL) equipped with a magnetic stirrer, an inert gas inlet and connected to a scrubber, octanedioic acid (440 g, 2.53 mol) and thionyl chloride (633 g, 5.32 mol) were added. The mixture was heated at 40 °C for 4 h with stirring until gas evolution was ceased. Consequently temperature was raised to 90 °C and bromine (832 g, 5.2 mol) was added dropwise to a mixture over a period of 4 h (while the flask was continuously irradiated with a 200 W mercury lamp). Finally, absolute methanol (250 mL) was added dropwise (vigorous gas evolution!) and a flask was cooled down to rt. The reaction mixture was washed with distilled water (50 mL), concentrated aqueous sodium acetate (100 mL) and aqueous sodium sulphite (100 mL). The separated organic phase was dried in a high vacuum at 90 °C to yield 864 g (95%) of the crude product, which was distilled at 140 °C under a vacuum (0.1-0.3 mbar) to yield 764 g (84%) of liquid and colourless diester **2**. IR (NaCl window, ν_{max} , cm^{-1}): 3003, 2953, 2862, 1740, 1437, 1357, 1273, 1218, 1196, 1157, 1010. Raman scattering (Stokes shift, ν_{max} , cm^{-1}): 2955, 2862, 1740, 1440. ^1H NMR (400 MHz, CDCl_3): δ_{H} 1.26-1.52 (m, 4H), 1.90-2.10 (m, 4H), 3.78 (s, 6H), 4.21 (t, 2H, J 7.0 Hz). ^{13}C NMR (100 MHz, CDCl_3): δ_{C} 26.4, 34.4, 45.2, 45.3, 52.9, 170.1. Anal. Calcd for $\text{C}_{10}\text{H}_{16}\text{Br}_2\text{O}_4$ (360.04): C, 33.36; H, 4.48; Br, 44.39. Found: C, 33.60; H, 4.31; Br, 44.62%. HRMS (ESI TOF): $[\text{M}+\text{Na}]^+$, found

380.9309, 382.9289, 384.9269. $[\text{C}_{10}\text{H}_{16}^{79}\text{Br}_2\text{O}_4+\text{Na}^+]$, $[\text{C}_{10}\text{H}_{16}^{79}\text{Br}^{81}\text{BrO}_4+\text{Na}^+]$ and $[\text{C}_{10}\text{H}_{16}^{81}\text{Br}_2\text{O}_4+\text{Na}^+]$ require 380.9307, 382.9287 and 384.9267, respectively.

(2*R,7*S**)-Dimethyl 1-methylazepane-2,7-dicarboxylate (4) and 8,10-dimethyl-8,10-diazabicyclo[4.3.1]decan-7,9-dione (6a).** To a glass liner (250 mL) methylamine (9.4 g, 303 mmol, dissolved in 100 mL of dry THF) and compound **2** (36 g, 100 mmol, dissolved in 100 mL of dry THF) were added. The liner was placed in a high pressure stainless steel reactor and the reaction mixture was heated with stirring at 120 °C for 2 h. Then the reaction mixture was filtered and the solvent was evaporated at reduced pressure. The residue was distilled at 140 °C under vacuum (0.1-0.3 mbar) to yield 13.0 g of a crude product, which was purified by column chromatography on silica gel (eluent: hexane-ethyl acetate, 5:1) to yield 6.5 g (28%) of compound **4** as a colourless liquid. IR (NaCl window, ν_{max} , cm^{-1}): 2949, 2864, 1736, 1677, 1437, 1308, 1197, 1170, 1084, 1022. Raman scattering (Stokes shift, ν_{max} , cm^{-1}): 2951, 2865, 1728, 1449. ^1H NMR (300 MHz, CDCl_3): δ_{H} 1.35-1.60 (m, 4H), 1.68-1.84 (m, 2H), 1.88-2.03 (m, 2H), 2.46 (s, 3H), 3.62 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 25.0, 30.4, 42.7, 51.4, 64.9, 174.4. Anal. Calcd for $\text{C}_{11}\text{H}_{19}\text{NO}_4$ (229.27): C, 57.62; H, 8.35; N, 6.11. Found: C, 57.78; H, 8.30; N, 6.20%. HRMS (ESI TOF): $[\text{M}+\text{H}]^+$, found 230.1386. $[\text{C}_{11}\text{H}_{19}\text{NO}_4+\text{H}^+]$ requires 230.1387.

The vacuum distillation residue, obtained after evaporation of azepane **4** as described above, was heated in original 100 ml distillation flask with stirring at 200 °C under argon atmosphere for 6 h. Then the reaction mixture was distilled at 160 °C under a vacuum (<0.2 mbar) to yield 6.0 g of a crude product. Product was redistilled in vacuum (<0.1 mbar) at 120 °C (yield 2.80 g) and once again for 5 h at 80 °C to afford compound **6a** as a greenish-yellow liquid. Yield 2.0 g (10%). IR (NaCl window, ν_{max} , cm^{-1}): 2937, 2863, 1727, 1675, 1442, 1355, 1308, 1151, 1061. Raman scattering (Stokes shift, ν_{max} , cm^{-1}): 2942, 2865, 1725, 1455, 1290, 1026, 605. ^1H NMR (400 MHz, CDCl_3): δ_{H} 1.36-1.48 (m, 2H), 1.63-1.75 (m, 2H), 1.96-2.16 (m, 4H), 2.55 (s, 3H), 3.16 (s, 3H), 3.63-3.68 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ_{C} 24.4, 25.4, 32.4, 44.8, 63.5, 174.3. HRMS (ESI TOF): $[\text{M}+\text{H}]^+$, found 197.1283. $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_2$ requires 197.1285.

Methyl (2*R,7*S**)-7-(benzylcarbamoyl)-1-methylazepane-2-carboxylate (5b).** A round-bottom flask (25 mL) was equipped with a magnetic stirrer and a Vigreux column. Compound **4** (1.75 g, 7.6 mmol), benzyl amine (0.875 g, 8.2 mmol) and xylene (3 mL) were added and the reaction mixture was heated at 120 °C with stirring over a period of 20 h under argon. The solvent was evaporated at reduced pressure and then unreacted starting materials were removed under a vacuum (<0.1 mbar) at 100 °C. The residue was crystallized from ethyl acetate (3 mL) to yield colourless crystalline azepane **5b** (0.8 g). After filtration of the product, the filtrate was concentrated and kept at -18 °C for 24 h to give an additional amount of the azepane **5b**. The total yield 1.60 g (69%). White solid, mp 82-84 °C. IR (KBr, ν_{max} , cm^{-1}): 3269 (N-H), 3269, 3027, 2932, 2878, 2820, 1723 (C=O, ester), 1647 (C=O, amide), 1518, 1455, 1360, 1217, 1199, 1146. Raman scattering (Stokes shift ν_{max} , cm^{-1}): 3069, 3052, 3036, 2933, 2887, 2821, 1724, 1647, 1603, 1587, 1455, 1434, 1290, 1230, 1205, 1002. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ_{H} 1.36-1.55 (m, 2H, 3- CH_2), 1.42-1.49 (m, 2H, 4- CH_2), 1.72-1.92 (m, 2H, 2- CH_2), 1.87-1.97 (m,

2H, 6-CH₂), 2.41 (s, 3H, NCH₃), 3.32 (dd, *J* 7.5, 5.0 Hz, 2-H), 3.56 (s, 3H, OCH₃), 3.69 (dd, *J* 7.6, 4.7 Hz, 7-H), 4.26-4.37 (m, 2H, CH₂-benzyl), 7.20-7.39 (m, 5H, ArH), 8.45 (br s, 1H, NH). HRMS (ESI TOF): [M+H]⁺, found 305.1864. [C₁₇H₂₄N₂O₃+H⁺] requires 305.1860.

8-Benzyl-10-methyl-8,10-diazabicyclo[4.3.1]decan-7,9-dione (6b). A round-bottom flask (500 mL) was equipped with a magnetic stirrer and a Vigreux column (with a mounted Claisen adapter, a side-on Liebig condenser and a top inert gas inlet). Compound **4** (158.6 g, 692 mmol), benzyl amine (78 g, 729 mmol) and xylene (150 mL) were added and the reaction mixture was heated at 160 °C (oil bath temperature) with stirring over a period of 72 h under argon. Formed methanol was removed by continual rectification. The solvent (xylene) was evaporated at reduced pressure and then unreacted starting materials were removed under vacuum (0.1-0.3 mbar) at 120 °C. The residue was heated at 205 °C for 24 h under argon. Finally, the mixture was distilled at 180 °C under a vacuum (0.1-0.3 mbar). The collected condensate was crystallized from ethyl acetate (20 mL) to yield dione **6b** (55.0 g). After filtration of the product, the filtrate was kept at -18 °C for 24 h to give an additional amount of the dione **6b**. The total yield 79.2 g (42%). Colourless crystals, mp 68-69 °C. IR (KBr, $\nu_{\max}$, cm⁻¹): 2944, 1722, 1670, 1457, 1435, 1340, 1191, 742, 704. Raman scattering (Stokes shift, $\nu_{\max}$, cm⁻¹): 3055, 3040, 2946, 1721, 1452, 1435, 1002. ¹H NMR (300 MHz, CDCl₃): δ_{H} 1.30-1.46 (m, 3H), 1.58-1.74 (m, 2H), 1.92-2.16 (m, 2H), 2.53 (s, 3H); 3.66 (dd, 2H, *J* 7.0, 3.7 Hz), 4.98 (s, 2H), 7.18-7.40 (m, 5H). ¹³C NMR (75 MHz, CDCl₃): δ_{C} 24.3, 32.4, 42.1, 44.9, 63.6, 127.3, 128.3, 128.7, 136.9, 173.8. Anal. Calcd for C₁₆H₂₀N₂O₂ (272.34): C, 70.56; H, 7.40; N, 10.29. Found: C, 70.48; H, 7.30; N, 10.44%. HRMS (ESI TOF): [M+H]⁺, found 273.1599. [C₁₆H₂₀N₂O₂+H⁺] requires 273.1598.

8,10-Dimethyl-8,10-diazabicyclo[4.3.1]decane (7a). To a round-bottom flask (50 mL) equipped with a magnetic stirrer, an Allihn condenser and an argon adapter, compound **6a** (2.8 g, 14.2 mmol), absolute dioxane (15 mL) and LiAlH₄ (pellets, 1.0 g, 26.3 mmol) were placed and the mixture was stirred in an oil bath at 120 °C for 20 h under argon atmosphere. The reaction mixture was cooled down and a mixture of water (1 mL) and dioxane (2 mL) was added dropwise under vigorous stirring. After 1 h to the mixture an aqueous NaOH solution (30%, 4 mL) was added. The formed inorganic solids were filtered off, the organic phase was separated and evaporated under reduced pressure. The resulting liquid was purified by distillation under a vacuum (0.1-0.2 mbar) at 60 °C to afford the target product **7a**, as a colourless liquid. Yield 1.2 g (50%). IR (ATR, $\nu_{\max}$, cm⁻¹): 2923, 2851, 2784, 1676, 1461, 1442, 1279, 1168, 1065. Raman scattering (Stokes shift, $\nu_{\max}$, cm⁻¹): 2933, 2887, 2821, 1724, 1605, 1587, 1458, 1434, 1290. ¹H NMR (400 MHz, CDCl₃): δ_{H} 1.54-1.68 (m, 4H), 1.82-2.04 (m, 4H), 2.15 (s, 3H), 2.20 (dd, 2H, *J* 10.8, 4.3 Hz), 2.43 (d, 2H, *J* 10.9 Hz), 2.59 (s, 3H), 2.90-2.95 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ_{C} 26.2, 33.4, 42.1, 47.0, 56.6, 59.6. HRMS (ESI TOF): [M+H]⁺, found 169.1697. [C₁₀H₂₀N₂+H⁺] requires 169.1699.

8-Benzyl-10-methyl-8,10-diazabicyclo[4.3.1]decane (7b). To a round-bottom flask (500 mL) equipped with a magnetic stirrer, an Allihn condenser and an argon adapter, compound **6b** (31.3 g, 115 mmol), absolute dioxane (250 mL) and LiAlH₄ (pellets, 5.6 g, 147 mmol) were placed and the mixture was stirred at 120 °C for 20 h under argon atmosphere. The reaction mixture was

cooled down and a mixture of water (6 mL) and dioxane (10 mL) was added dropwise under vigorous stirring. After 1 h an aqueous NaOH solution (30%, 30 mL) was added. The formed inorganic solids were filtered off, the organic phase was separated and evaporated under reduced pressure. The residue was purified by distillation under a vacuum (0.1-0.2 mbar) at 125 °C to afford the target product **7b**, as a colourless liquid. Yield 19.1 g (68%). IR (NaCl window, $\nu_{\max}$, cm^{-1}): 2915, 2799, 1674, 1453, 1239, 1174, 1062, 731, 698. Raman scattering (Stokes shift, $\nu_{\max}$, cm^{-1}): 3056, 2912, 2809, 1604, 1448, 1004. ^1H NMR (300 MHz, CDCl_3): δ_{H} 1.55-1.75 (m, 4H), 1.92-2.08 (m, 4H), 2.30 (dd, 2H, J 11.3, 4.0 Hz), 2.50 (d, 2H, J 10.6 Hz), 2.62 (s, 3H), 2.90-2.98 (m, 2H), 3.40 (s, 2H), 7.20-7.38 (m, 5H). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 26.2, 33.4, 42.1, 56.7, 57.5, 63.8, 126.8, 128.1, 128.9, 138.9. Anal. Calcd for $\text{C}_{16}\text{H}_{24}\text{N}_2$ (244.38): C, 78.64; H, 9.90; N, 11.46. Found: C, 78.36; H, 9.82; N, 11.58%. HRMS (ESI TOF): $[\text{M}+\text{H}]^+$, found 245.2012. $[\text{C}_{16}\text{H}_{24}\text{N}_2+\text{H}^+]$ requires 245.2012.

10-Methyl-8,10-diazabicyclo[4.3.1]decane (8). To a glass liner (300 mL) under an argon atmosphere absolute ethanol (80 mL), compound **7b** (19.0 g, 77 mmol) and 10% palladium on charcoal (0.8 g) were added. The hydrogenation was carried out in a high pressure stainless steel reactor by stirring the mixture at 100 °C under hydrogen atmosphere (50 bar) for 40 h. After cooling down and decompression, the reaction mixture was filtered off, the solvent evaporated at reduced pressure and the resulting liquid was distilled at 70 °C under a vacuum (0.1-0.2 mbar) to afford the target compound **8** as a waxy solid. Yield 9.5 g (79%). ^1H NMR (300 MHz, CDCl_3): δ_{H} 1.45-1.75 (m, 6H), 1.87-2.00 (m, 2H), 2.16 (s, 1H), 2.49 (s, 3H), 2.51 (d, 2H, J 12.4 Hz), 2.65 (m, 2H), 2.95 (dd, 2H, J 12.1, 4.0 Hz). ^{13}C NMR (75 MHz, CDCl_3): δ_{C} 26.1, 32.6, 42.5, 49.6, 55.4. Anal. Calcd for $\text{C}_9\text{H}_{18}\text{N}_2$ (154.25): C, 70.08; H, 11.76; N, 18.16. Found: C, 70.28; H, 11.74; N, 18.02%. HRMS (ESI TOF): $[\text{M}+\text{H}]^+$, found 155.1543. $[\text{C}_9\text{H}_{18}\text{N}_2+\text{H}^+]$ requires 155.1543.

References

1. O'Donnell, J. C.; Peng, L.; O'Neill, B. T.; Arnold, E. P.; Mather, R. J.; Sands, S. B.; Shrikhande, A.; Lebel, L. A.; Spracklin, D. K.; Nedza, F. M. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4747-4751.
<http://dx.doi.org/10.1016/j.bmcl.2009.06.059>
PMid:19576766
2. Biton, B.; Bergis, O. E.; Galli, F.; Nedelec, A.; Lochead, A. W.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R.; Chesney, F.; Léonardon, J.; Granger, P.; Debono, M. W.; Bohme, G. A.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Vigé, X.; Voltz, C.; Rouquier, L.; Souilhac, J.; Santucci, V.; Gueudet, C.; Françon, D.; Steinberg, R.; Griebel, G.; Oury-Donat, F.; George, P.; Avenet, P.; Scatton, B. *Neuropsychopharmacol.* **2007**, *32*, 1-16.

- <http://dx.doi.org/10.1038/sj.npp.1301189>
PMid:17019409
3. Peters, D.; Timmermann, D. B.; Olsen, G. M.; Nielsen, E. Ø.; Jørgensen, T. D. U.S. Patent 7 612 074 B2, 2009.
 4. Audouze, K.; Nielsen, E. Ø.; Olsen, G. M.; Ahring, P.; Jørgensen, T. D.; Peters, D.; Liljefors, T.; Balle, T. *J. Med. Chem.* **2006**, *49*, 3159-3171.
<http://dx.doi.org/10.1021/jm058058h>
PMid:16722635
 5. Galli, F.; Leclerc, O.; Lochead, A. U.S. Patent 6 844 337 B2, 2005.
 6. Barlocco D.; Cignarella G.; Tondi D.; Vianello P.; Villa S.; Bartolini A.; Ghelardini C.; Galeotti N.; Anderson D. J.; Kuntzweiler T. A.; Colombo D.; Toma L. *J. Med. Chem.* **1998**, *41*, 674-681.
<http://dx.doi.org/10.1021/jm970427p>
PMid:9513595
 7. McGuirk, P. R.; Jefson, M. R.; Mann, D. D.; Elliot, N. C.; Chang, P.; Cisek, E. P.; Cornell, C. P.; Gootz, T. D.; Haskell, S. L.; Hindhahl, M. S.; LaFleur, L. J.; Rosenfeld, M. J.; Shryock, T. R.; Silvia, A. M.; Weber, F. H. *J. Med. Chem.* **1992**, *35*, 611-620.
<http://dx.doi.org/10.1021/jm00082a001>
 8. Deuther-Conrad, W.; Fisher, S.; Hiller, A.; Becker, G.; Cumming, P.; Xiong, G.; Funke, U.; Sabri, O.; Peters, D.; Brust, P. *Eur. J. Nucl. Mol. Imaging* **2011**, *38*, 1541-1549.
<http://dx.doi.org/10.1007/s00259-011-1808-y>
PMid:21484373
 9. Brust, P.; Peters, D.; Deuther-Conrad, W. *Curr. Drug Targets* **2012**, *13*, 594-601.
PMid:22300025
 10. Audrain, H.; Bender, D.; Scheel-Krüger, J.; Nielsen, E. Ø.; Olsen, G. M.; Peters, D.; Cumming, P. *J. Labelled Compd. Radiopharm.* **2003**, *46*, 873-882.
<http://dx.doi.org/10.1002/jlcr.726>
 11. Peters, D.; Olsen, G. M.; Nielsen, E. O.; Timmermann, D. B.; Loechel, S. C.; Christensen, J. K.; Dyhring, T. WO 2007135121, 2007.
 12. Rubstov, M. V.; Mikhlin, E. E.; Vorob'eva, V. Ya.; Yanina, A. D. *Zh. Obshch. Khim.* **1964**, *34*, 2222-2226.
 13. Vervisch, K.; D'hooghe, M.; Törnroos, K. W.; De Kimpe, N. *J. Org. Chem.* **2010**, *75*, 7734-7744.
<http://dx.doi.org/10.1021/jo101646u>
PMid:20977252
 14. Cignarella, G.; Nathansohn, G.; Occelli, E. *J. Org. Chem.* **1961**, *26*, 2747-2755.
<http://dx.doi.org/10.1021/jo01066a031>
 15. Paliulis, O.; Peters, D.; Miknius, L.; Šačkus, A. *Org. Prep. Proced. Int.* **2007**, *39*, 86-89.
<http://dx.doi.org/10.1080/00304940709458585>

16. Blackman, S. W.; Baltzly, R. *J. Org. Chem.* **1961**, *26*, 2750-2755.
<http://dx.doi.org/10.1021/jo01066a032>
17. Huang, L. J.; Teng, D. W. *Chin. Chem. Lett.* **2011**, *22*, 523-526.
<http://dx.doi.org/10.1016/j.cclet.2010.11.030>
18. Goss, F. R.; Ingold, C. K. *J. Chem. Soc.* **1926**, 1471-1477, and references cited therein.
<http://dx.doi.org/10.1039/jr9262901471>
19. Satoh, S.; Itoh, M.; Sugimoto, H.; Tokuda, M. Bulletin of the Faculty Engineering, Hokkaido Univ. 1981, No. 102, 33-42.
20. Zhang, W.; Liang, Q.; Li, H.; Meng, X.; Li, Z. *Tetrahedron* **2013**, *69*, 664-672.
<http://dx.doi.org/10.1016/j.tet.2012.11.004>
21. Johnson, T. A.; Sohn, J.; Vaske, Y. M.; White, K. N.; Cohen, T. L.; Vervoort, H. C.; Tenney, K.; Valeriote, F. A.; Bjeldanes, L. F.; Crews, P. *Bioorg. Med. Chem.* **2012**, *20*, 4348-4355.
<http://dx.doi.org/10.1016/j.bmc.2012.05.043>
PMid:22705020 PMCID:PMC3417756
22. Hoffman, H.; Haag-Richter, S.; Kurz, M.; Tietgen, H. U.S. Patent 7 153 846, 2004.
23. Kulanthaivel, P.; Hallock, Y. F.; Boros, C.; Hamilton, S. M.; Janzen, W. P.; Ballas, L. M.; Loomis, C. R.; Jiang, J. B.; Katz, B.; Steiner, J. R.; Clardy, J. *J. Am. Chem. Soc.* **1993**, *115*, 6452-6453.
<http://dx.doi.org/10.1021/ja00067a087>
24. Gilmet, J.; Sullivan, B.; Hudlicky, T. *Tetrahedron* **2009**, *65*, 212-220.
<http://dx.doi.org/10.1016/j.tet.2008.10.070>
25. Nú- ez-Villanueva, D.; Infantes, L.; García-López, M. T.; González-Mu- iz, R.; Martín- Martínez, M. *J. Org. Chem.* **2012**, *77*, 9833-9839.
26. Cini, E.; Bifulco, G.; Menchi, G.; Rodriquez, M.; Taddei, M. *Eur. J. Org. Chem.* **2012**, *77*, 2133-2141.
<http://dx.doi.org/10.1002/ejoc.201101387>
27. Braun, S.; Kalinowski, H.-O.; Berger, S. 150 and More Basic NMR Experiments; Wiley-VCH: Weinheim, 1998, p 596.